SCHEDULE: Janus Henderson Discloses 6% Stake in Maze Therapeutics

Janus Henderson Group plc has disclosed a 6.0% beneficial ownership stake in Maze Therapeutics, Inc., holding 2,625,089 common shares.

Summary

• Janus Henderson Group plc reported beneficial ownership of 2,625,089 shares of Common Stock in Maze Therapeutics, Inc.
• This represents 6.0% of Maze Therapeutics, Inc.'s outstanding Common Stock.
• Janus Henderson Group plc, a Jersey-based entity, holds shared voting and dispositive power over all reported shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported stake.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine disclosure of beneficial ownership and does not contain operational or financial performance data.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence.
• Company Management: Awareness of a large institutional holder, which could influence future engagement.

Key Dates

Keywords

Maze Therapeutics, Janus Henderson Group, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13G, Investment Adviser, Biotechnology, Pharmaceuticals